(reported by the Company)
No items found
The company has been founded to develop therapies to address fibrosis, a condition associated with many chronic diseases where tissue damage leads to scarring and a loss of organ function. Inosi recognises the importance of close and early engagement between academic researchers and industry partners to ensure new therapy development programs are informed and aligned with addressing unmet patient and market needs.
|Category:||Health & biotech|
|ASX Listing Code (if applicable):|
|Year of Commencement:||2019|